These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 30100077)
1. Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer. Iagaru A; Minamimoto R PET Clin; 2018 Jul; 13(3):383-393. PubMed ID: 30100077 [TBL] [Abstract][Full Text] [Related]
3. Single photon emission computed tomography (SPECT) and SPECT/low-dose computerized tomography did not increase sensitivity or specificity compared to planar bone scintigraphy for detection of bone metastases in advanced breast cancer. Haraldsen A; Bluhme H; Røhl L; Pedersen EM; Jensen AB; Hansen EB; Nellemann H; Rasmussen F; Morsing A Clin Physiol Funct Imaging; 2016 Jan; 36(1):40-6. PubMed ID: 25257661 [TBL] [Abstract][Full Text] [Related]
4. Breast cancer: role of SPECT and PET in imaging bone metastases. Ben-Haim S; Israel O Semin Nucl Med; 2009 Nov; 39(6):408-15. PubMed ID: 19801220 [TBL] [Abstract][Full Text] [Related]
5. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709 [TBL] [Abstract][Full Text] [Related]
6. Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. Cook GJ; Azad GK; Goh V J Nucl Med; 2016 Feb; 57 Suppl 1():27S-33S. PubMed ID: 26834098 [TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330 [TBL] [Abstract][Full Text] [Related]
8. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Chua S; Gnanasegaran G; Cook GJ Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221 [TBL] [Abstract][Full Text] [Related]
9. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer. Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906 [TBL] [Abstract][Full Text] [Related]
10. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167 [TBL] [Abstract][Full Text] [Related]
11. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan? Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321 [TBL] [Abstract][Full Text] [Related]
13. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series. Koolen BB; Vegt E; Rutgers EJ; Vogel WV; Stokkel MP; Hoefnagel CA; Fioole-Bruining A; Vrancken Peeters MJ; Valdés Olmos RA Ann Nucl Med; 2012 Jan; 26(1):86-91. PubMed ID: 21953212 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Qiu ZL; Xue YL; Song HJ; Luo QY Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353 [TBL] [Abstract][Full Text] [Related]
15. [Nuclear medicine diagnosis of bone metastases]. Strobel K Praxis (Bern 1994); 2009 Nov; 98(22):1293-7. PubMed ID: 20029782 [TBL] [Abstract][Full Text] [Related]
16. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer. Ng SP; David S; Alamgeer M; Ganju V Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029 [TBL] [Abstract][Full Text] [Related]
17. A Comparison of Accuracy of Planar and Evolution SPECT/CT Bone Imaging in Differentiating Benign from Metastatic Bone Lesions. Teyateeti A; Tocharoenchai C; Muangsomboon K; Komoltri C; Pusuwan P J Med Assoc Thai; 2017 Jan; 100(1):100-10. PubMed ID: 29911774 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging. Pires AO; Borges US; Lopes-Costa PV; Gebrim LH; da Silva BB Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():138-41. PubMed ID: 25037283 [TBL] [Abstract][Full Text] [Related]
19. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging. Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015 [TBL] [Abstract][Full Text] [Related]
20. [Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques]. Withofs N; Collignon J; Rorive A; Jerusalem G; Hustinx R Rev Med Liege; 2011; 66(5-6):288-90. PubMed ID: 21826964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]